Mandatory notification of trade
Oncoinvent ASA (ONCIN) · publisert 2025-11-03 07:55 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass | Tolket via |
|---|---|---|---|---|---|---|---|---|
| Charles Gillies O'Bryan-Tear | Primary insider and chairperson of the board of directors | other | 420 938 | 0 NOK | 2025-11-03 | NO0013251173 | – | rules · til gjennomgang |
| Gro Elisabeth Hjellum | Primary insider and Chief Operating Officer | other | 48 107 | 0 NOK | 2025-11-03 | NO0013251173 | – | rules · til gjennomgang |
| Kristine Lofthus | Primary insider and Chief Production Officer | other | 8 017 | 0 NOK | 2025-11-03 | NO0013251173 | – | rules · til gjennomgang |
| Stian Brekke | Primary insider and Head of Regulatory Affairs | other | 45 100 | 0 NOK | 2025-11-03 | NO0013251173 | – | rules · til gjennomgang |
| Anne Cecilie Alvik | Primary insider and Head of Quality Assurance | other | 15 875 | 0 NOK | 2025-11-03 | NO0013251173 | – | rules · til gjennomgang |
| Abakus Invest AS nærstående | Close associate to primary insider and Chief Executive Officer, Øystein Soug. | other | 180 402 | 0 NOK | 2025-11-03 | NO0013251173 | – | rules · til gjennomgang |
| Hadean Capital I AS nærstående | Close associate to primary insider and board member of the board of directors, Ingrid Teigland Akay. | other | 10 621 231 | 0 NOK | 2025-11-03 | NO0013251173 | – | rules · til gjennomgang |
| HVentures Capital I AB nærstående | Close associate to primary insider and board member of the board of directors, Ingrid Teigland Akay. | other | 4 817 485 | 0 NOK | 2025-11-03 | NO0013251173 | – | rules · til gjennomgang |
| Teakay Invest AS nærstående | Close associate to primary insider and board member of the board of directors, Ingrid Teigland Akay. | other | 297 187 | 0 NOK | 2025-11-03 | NO0013251173 | – | rules · til gjennomgang |
| Itza AS nærstående | Close associate to primary insider and Chief Financial Officer, Tore Kvam. | other | 72 160 | 0 NOK | 2025-11-03 | NO0013251173 | – | rules · til gjennomgang |
| K OG K AS nærstående | Close associate to primary insider and board member of the board of directors, Kari Grønås. | other | 90 201 | 0 NOK | 2025-11-03 | NO0013251173 | – | rules · til gjennomgang |
Vedlegg
- 2025_11_03_vederlags_aksjer.pdf (tekst hentet ut)
- PDMR_Attachment_allocation_of_consideration_shares.pdf (tekst hentet ut)
Meldingstekst
Oslo, 3 November 2025: Reference is made to the stock exchange announcement
published by Oncoinvent ASA (the "Company") on 29 October 2025 regarding the
completion of the merger between the Company and the former Oncoinvent ASA (reg.
no. 995 764 458) ("Oncoinvent") (the "Merger").
In connection with completion of the Merger, the former shareholders of
Oncoinvent, including certain primary insiders of the Company and their close
associates, have today been allocated consideration shares in the Company. More
information about the allocation of consideration shares is included in the
Prospectus published on 28 October 2025.
Please see the attached forms for further details on the allocation of
consideration shares in the Merger to the Company's primary insiders and their
close associates.
For more information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
About Oncoinvent ASA
Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. One Phase 1 trial and one Phase 1/2a
trial have been completed and one randomized Phase 2 trial is currently ongoing
in the US, UK and Europe. Early clinical efficacy data are highly encouraging,
and no serious toxicity or safety concerns have been reported to date. The
Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art
manufacturing facility to produce drug products for clinical trials in Nydalen,
Oslo. Oncoinvent is listed on Euronext Oslo Børs.
This information is subject to the disclosure requirements in article 19 of
Regulation EU 596/2014 (the EU Market Abuse Regulation) and Section 5-12 of the
Norwegian Securities Trading Act.